Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

TELA
TELA Bio, Inc. Common Stock
stock NASDAQ

At Close
Jan 23, 2026 3:52:30 PM EST
0.9887USD+2.979%(+0.0286)32,791
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Jan 22, 2026 9:15:30 AM EST
0.9750USD+1.552%(+0.0149)0
After-hours
Jan 20, 2026 4:53:30 PM EST
1.01USD+8.590%(+0.08)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 10, 2021
04:47PM EST  TELA Bio Q3 EPS $(0.57) Misses $(0.52) Estimate, Sales $7.70M Beat $7.55M Estimate   Benzinga
04:01PM EST  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported third quarter 2021 financial results.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
11:31AM EST  TELA Bio Announces Publication Of 12-Month Results From BRAVO Study   Benzinga
07:00AM EST  -- 12-month follow-up data in 75 patients treated with OviTex Reinforced Tissue Matrix (RTM) for ventral hernia repair demonstrates an overall hernia recurrence rate of 2.7%. -- Final 24-month analysis shows hernia recurrence rate remains below 5%.   GlobeNewswire Inc
Nov 8, 2021
07:00AM EST  TELA Bio to Participate in Three Upcoming Conferences   GlobeNewswire Inc
Nov 1, 2021
07:19AM EDT  TELA Bio And Next Science Enter Distribution Deal In Plastic Reconstructive Market For Anti-Biofilm Surgical Wash   RTTNews
07:10AM EDT  TELA Bio And Next Science Enter Into Exclusive Distribution Agreement In The Plastic Reconstructive Market For Advanced Anti-Biofilm Surgical Wash   Benzinga
07:00AM EDT  TELA Bio and Next Science Enter into Exclusive Distribution   GlobeNewswire Inc
Oct 27, 2021
04:01PM EDT  TELA Bio to Announce Third Quarter 2021 Financial Results   GlobeNewswire Inc
Sep 27, 2021
12:36PM EDT  How Bad Are TELA Bio's Earnings? | Return On Capital Employed   Benzinga
07:53AM EDT  TELA Bio, Inc. (TELA), a commercial-stage medical technology company, on Monday announced the appointment of Roberto Cuca as its new Chief Operating Officer and Chief Financial Officer.   RTTNews
07:13AM EDT  TELA Bio Appoints Roberto Cuca As COO And CFO   RTTNews
07:04AM EDT  TELA Bio Appoints Roberto Cuca As Chief Operating Officer And Chief Financial Officer   Benzinga
07:00AM EDT  TELA Bio Appoints Roberto Cuca as Chief Operating Officer and   GlobeNewswire Inc
Sep 13, 2021
07:00AM EDT  TELA Bio Announces New Data on Use of OviTex in a   GlobeNewswire Inc
Aug 16, 2021
07:00AM EDT  TELA Bio's OviTex Reinforced Tissue Matrix to be   GlobeNewswire Inc
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
05:03PM EDT  TELA Bio: Q2 Earnings Insights   Benzinga
04:11PM EDT  TELA Bio Sees FY21 Sales $28M-$30M vs. $29.08M Est.   Benzinga
04:10PM EDT  TELA Bio Q2 EPS $(0.57) Misses $(0.52) Estimate, Sales $7.56M Beat $6.31M Estimate   Benzinga
04:01PM EDT  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported second quarter 2021 financial results.   GlobeNewswire Inc
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 10, 2021
10:51AM EDT  Earnings Outlook For TELA Bio   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 3, 2021
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in Canaccord Genuitys 41st Annual Growth Conference.   GlobeNewswire Inc
Jul 28, 2021
07:00AM EDT  TELA Bio to Announce Second Quarter 2021 Financial Results   GlobeNewswire Inc
Jul 21, 2021
08:29AM EDT  TELA Bio Highlights NHS Surgeon First In Europe To Implant Co's OviTex LPR Reinforced Tissue Matrix   Benzinga
08:29AM EDT  TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced today the first use of its OviTex LPR Reinforced Tissue Matrix in Europe.   GlobeNewswire Inc
Jun 14, 2021
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the JMP Securities Life Sciences Conference.   GlobeNewswire Inc
Jun 2, 2021
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that it has appointed John Nosenzo, the Chief Commercial Officer of Bioventus Inc., to its board of directors effective June 2, 2021.   GlobeNewswire Inc
May 25, 2021
07:00AM EDT  TELA Bio Names Marissa Conrad as Vice President of Clinical   GlobeNewswire Inc
May 24, 2021
11:03AM EDT  ROCE Insights For TELA Bio   Benzinga
May 21, 2021
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company plans to participate in two upcoming investor conferences.   GlobeNewswire Inc
May 19, 2021
09:16AM EDT  TELA Bio Launches Post Market Study Of OviTex In Hernia Surgery   Benzinga
07:23AM EDT  TELA Bio Begins BRAVO II Study Of OviTex For Robotic Repair Of Ventral Hernias   RTTNews
07:08AM EDT  TELA Bio Initiates BRAVO II Study Of OviTex For Robotic Repair Of Ventral Hernias   Benzinga
07:00AM EDT  TELA Bio Initiates BRAVO II Study of OviTex for the   GlobeNewswire Inc
May 13, 2021
04:31PM EDT  TELA Bio: Q1 Earnings Insights   Benzinga
04:24PM EDT  TELA Bio Q1 EPS $(0.56) Misses $(0.48) Estimate, Sales $5.88M Beat $5.46M Estimate   Benzinga
04:02PM EDT  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the first quarter ended March 31, 2021.   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
Apr 29, 2021
04:00PM EDT  TELA Bio to Announce First Quarter 2021 Financial Results   GlobeNewswire Inc
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 24, 2021
04:28PM EDT  Recap: TELA Bio Q4 Earnings   Benzinga
04:02PM EDT  TELA Bio Sees FY21 Sales $27M-$30M vs $33.13M Est.   Benzinga
04:02PM EDT  TELA Bio Q4 EPS $(0.54) Misses $(0.49) Estimate, Sales $5.70M Miss $5.80M Estimate   Benzinga
04:01PM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the fourth quarter and full year ended December 31, 2020.   GlobeNewswire Inc
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
04:29AM EDT  Earnings Scheduled For March 24, 2021   Benzinga
Mar 18, 2021
07:00AM EDT  TELA Bio Announces 12-Month Analysis from BRAVO Study of   GlobeNewswire Inc
Mar 2, 2021
07:00AM EST  TELA Bio to Report Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
Feb 4, 2021
07:00AM EST  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.   GlobeNewswire Inc
Jan 14, 2021
07:09AM EST  TELA Bio Expects Q4 Revenue To Be $5.5 Mln-5.7 Mln   RTTNews
07:01AM EST  TELA Bio Sees Q4 Sales $5.5M-$5.7M Vs. $6.01M Est., FY20 Sales $18M-$18.2M Vs. $18.55M Est.   Benzinga
07:00AM EST  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2020.   GlobeNewswire Inc
Jan 6, 2021
07:00AM EST  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the 23rd Annual Needham Virtual Growth Conference.   GlobeNewswire Inc
Jan 5, 2021
07:10AM EST  TELA Bio Names Bruce Freedman As VP Of Clinical Development   RTTNews
07:00AM EST  Bruce Freedman, M.D.joins innovative MedTech company to advocate for more natural surgical hernia mesh options   GlobeNewswire Inc
Dec 18, 2020
04:54PM EST  Tela Bio Files For Mixed Shelf Of Upto $150M   Benzinga
Nov 24, 2020
07:00AM EST  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 11, 2020
04:34PM EST  Recap: TELA Bio Q3 Earnings   Benzinga
04:11PM EST  TELA Bio Q3 EPS $(0.53) Misses $(0.49) Estimate, Sales $5.30M Beat $4.58M Estimate   Benzinga
04:05PM EST  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the third quarter ended September 30, 2020.   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
04:09AM EST  Earnings Scheduled For November 11, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Oct 21, 2020
04:05PM EDT  TELA Bio to Announce Third Quarter 2020 Financial   GlobeNewswire Inc
Sep 25, 2020
07:03AM EDT  TELA Bio Highlights Presentation Of Additional Data From BRAVO Study Of OviTex For Ventral Hernia Repair   Benzinga
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.   GlobeNewswire Inc
Sep 2, 2020
07:00AM EDT  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced today that the company plans to participate in two upcoming conferences.   GlobeNewswire Inc
Aug 13, 2020
09:50AM EDT  Piper Sandler Maintains Overweight on TELA Bio, Raises Price Target to $17   Benzinga
Aug 12, 2020
04:23PM EDT  TELA Bio Q2 EPS $(0.53) Beats $(0.59) Estimate, Sales $3.51M Beat $1.93M Estimate   Benzinga
04:05PM EDT  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020.   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 12, 2020   Benzinga
Jul 30, 2020
07:00AM EDT  TELA Bio to Participate at the Canaccord Genuity 40th Annual   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC